RNATICS - MAxL

[back to news overview]

^07/2024

RNATICS is the first tenant at MAxL

We welcome the first tenant in the “Munich Accelerator Life Sciences & Medicine” (MAxL) in Martinsried.

RNATICS GmbH is a young, innovative biotech company developing targeted nucleic acid therapies against inflammatory lung diseases applied via inhalation. The drugs are selectively delivered to lung macrophages, specific immune cells in the lung, targeting disease-causing, microRNAs (regulatory, non-coding RNAs).

The most advanced drug candidate, RCS-21, is currently in development for the treatment of patients with acute respiratory hyperinflammation after viral infections, such as influenza, RSV, or SARS-CoV-2. The clinical trial application was submitted to BfArM in Q3 2024 and upon approval, first-in-human phase I clinical trial will be started. The innovative trial design allows not only to demonstrate safety and tolerability but will also already show successful drug delivery to lung macrophages and target engagement of RCS-21.

In addition, novel treatments based on this targeting technology for chronic inflammatory lung diseases, such as COPD and ILD, and rare lung diseases are actively developed to expand the drug pipeline.

[view the team profile]